[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Monoclonal antibodies panitumumab and cetuximab target the epidermal growth factor receptor (EGFR) for metastatic colorectal cancer (mCRC).
• EGFR expression alone is insufficient for predicting treatment efficacy, necessitating the search for novel predictive biomarkers.
• Signaling pathway activation downstream of EGFR, including KRAS, BRAF, PIK3CA mutations, and PTEN inactivation, drives CRC progression.

Purpose of the Study:

• To identify and evaluate predictive biomarkers for anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
• To investigate the role of KRAS, BRAF, PIK3CA mutations, PTEN inactivation, and EGFR ligand overexpression in predicting treatment response.
• To explore gene expression profiling as a potential predictive tool for anti-EGFR therapy.

Main Methods:

• Analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in colorectal cancer tissues.
• Assessment of EGFR ligand overexpression as a predictive marker.
• Exploration of gene expression profiling for treatment decision-making.

Main Results:

• KRAS mutation is a recognized marker of resistance to cetuximab and panitumumab.
• Mutations in BRAF or PIK3CA, or loss of PTEN expression, may indicate resistance in KRAS wild-type tumors.
• EGFR ligand overexpression shows potential as a positive predictive marker.

Conclusions:

• KRAS mutation status is essential for clinical decision-making regarding anti-EGFR therapy in mCRC.
• Further research into BRAF, PIK3CA, PTEN, and EGFR ligands is needed to refine predictive models.
• Gene expression profiling requires prospective validation for clinical application in guiding anti-EGFR treatment.